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Regulation of blood pressure: 
A cybernetic mechanism residing in the kidney? 
Recent evidence that two separate and opposing 
secretions from the pancreas serve to regulate blood 
sugar suggests that other important constants of the 
“milieu interieur” may be subject to a double con- 
trol on the part of a single organ. The endocrine 
secretions of the kidney may well provide a second 
example, in this case as a regulating mechanism for 
control of the blood pressure. 
There is ample evidence that under circumstances 
of reduced perfusion pressure the kidney secretes a 
pressor substance which serves to elevate systemic 
arterial pressure. Although the nature of the secre- 
tion has not been clearly identified, it would seem 
to be renin, which originates from the juxta-glomer- 
ular cells and, through direct and indirect mecha- 
nisms, releases a variety of less complex molecules, 
such as angiotensin and aldosterone, substances 
which serve to elevate the blood pressure. Studies of 
shock and of the response of blood pressure to 
nephrectomy or to renal vascular surgery leave little 
doubt that the kidney does secrete acutely and 
chronically a humoral pressor substance, although 
detection of it in the blood by our present methods 
is extremely difficult. 
Evidence for a contrarily acting mechanism which 
originates in the kidney is also accumulating. The 
inhibiting effect of normal kidney tissue upon the 
development of renal “ischemic” hypertension is 
well recognized. Muirhead has located the cells which 
perform this function in the renal medulla, and he 
and Grollman have described an extract which, 
under special circumstances, has an antipressor 
effect. Mill& has recently isolated a substance from 
rabbit kidney medulla which has a prolonged anti- 
hypertensive action in the renal hypertensive rabbit. 
Furthermore, kidney transplants in man and animals 
rapidly normalize the blood pressure in cases of 
renal hypertension but do not produce hypotension. 
The kidney seems to stop releasing its antihyper- 
tensive secretion when the blood pressure reaches 
normal: Tobian has demonstrated in the rat that 
the depressor action of the normal kidney appears 
only when this organ is under increased perfusion 
pressure, whereas studies in our laboratory indicate 
that the depressor effect of kidney transplants, which 
is easy to demonstrate when the blood pressure is 
elevated by figure-of-eight ligation of the opposite 
kidney, does not lower the blood pressure of a 
normotensive animal. 
These observations corroborate the intimate and 
reciprocal relationship between normal and “ische- 
mic” kidneys which was described many years ago 
by Friedman and collaborators, further examined in 
the elegant experiments of Wilson and Byron on the 
“touched” and the “untouched” kidney, and re- 
cently extended by Gross, who has shown that the 
renin content of the contralateral kidney is reduced 
in the case of unilateral renal hypertension. This 
reciprocal relationship has been demonstrated in 
many other contexts since it was first described by 
Goldblatt in his classic experiments. A review of the 
literature and a presentation of some of the latest 
experiments in this field are referred to in a recent 
symposium, reprints of which are available on re- 
quest to interested investigators.* 
If indeed the kidney will some day prove to be 
the source of two oppositely acting secretions, both 
concerned with regulation of the blood pressure, of 
what importance would this conclusion be to the 
clinician and to the investigator? In the first place, 
such a finding would serve to reconcile the renal and 
*Symposium on Experimental Renal Hypertension. University 
of Michigan Medical Bulletin 27:175. 1961. Reprints may 
be obtained by writing to Dr. Walter Freyburger, The 
Upjohn Company, Kalamazoo, Mich. 
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renoprival explanations for the etiology of hyper- 
tension. In the second place, it might encourage in- 
vestigators to look for the pathogenesis of essential 
hypertension in terms of a deficiency of the appro- 
priate renal response to elevated blood pressure. In 
the third place, more widespread recognition of the 
antihypertensive role of the normal kidne), should 
cause surgeons to hesitate to remove “ischemic” 
kidneys when revascularization is at all possible in 
the treatment of renal vascular hypertension. Fi- 
nally, studies to isolate a hormone from the kidney 
which might regulate the blood pressure down to 
but not below the normal value would seem to 
offer more therapeutic advantages in the treat- 
ment of hypertension than the further development 
of nonspecific depressor substances. Discovery of 
such a substance in normal kidney tissue would in- 
troduce a new era in the treatment of hypertension 
comparable to that which followed the discovery of 
liver extract for the treatment of pernicious anemia. 
The significant investigations now proceeding in this 
direction deserve more attention than has so far been 
accorded to them in laboratories devoted to research 
in the problems of experimental and clinical hyper- 
tension. 
Sibley W. Hoobler, M.D. 
Professor of Internal Medicine 
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The use of steroids in pericarditis 
Pericarditis tends to be a recurrent disease, whether 
due to viral or bacterial infections, surgical incision 
of the pericardium, trauma, actinomycosis, or after 
myocardial infarction.’ Recurrences have been re- 
ported in as high as 63 per cent of the patients after 
mitral commissurotomy, but rates of 30 to 40 per 
cent have been more common.2 Recurrences have 
been noted in 18 to 36 per cent of the patients after 
so-called idiopathic pericarditis.3,4 In 100 patients 
who underwent open-heart operation for congenital 
defects, 30 per cent developed pericarditis after the 
operation.6 
The predominant symptom is distressing peri- 
cardial pain, although pleuritis and pneumonitis may 
also occur. Rarely, the disability from recurrent 
symptoms has been so great that total pericardiec- 
tomy has been necessary for the patient to obtain 
relief.6l7 Steroids have been of particular value in 
relieving pain. They may be effective at times when 
opiates are ineffective. Furthermore, they may lessen 
the dyspnea due to splinting of the chest, without 
the impairment of ventilation experienced with 
opiates. The antipyretic effect is beneficial but of 
secondary importance, except in the rare individual 
with high fever. In the critically ill child with acute 
rheumatic or other type of pericarditis, the response 
within 24 hours may be dramatic. The subsidence of 
tachypnea with slowing of the pulse rate, the dis- 
appearance of an anxious expression, improved appe- 
tite, and sense of well-being may be noteworthy. 
The impression has been gained that the sup- 
pression of inflammation with lessened formation of 
pericardial fluid may decrease the likelihood of peri- 
cardial tamponade. Often the elevated venous pres- 
sure may decrease within several days. At the present 
time there are no data to indicate that the course of 
a given attack of pericarditis is shortened, and pre- 
mature withdrawal of steroids often results in the 
“rebound phenomenon”2 with return of pain and 
fever. 
Steroids should be reserved for those who do not 
respond to salicylates, and those who are severely 
ill. They should not be used in those in whom tuber- 
culous pericarditis is suspected. The fear that virus 
infection might be disseminated under steroid ther- 
apy has not been borne out. 
Prednisone in doses of 40 to 60 mg. daily is usu- 
ally effective and should be gradually reduced by 
trial and error over a period of 2 to 3 weeks. If 
symptoms return with decrease in dosage, the 
amount should again be increased. The adminis- 
tration of gradually increased doses of aspirin during 
the period of withdrawal may lessen the likelihood 
of rebound and shorten the course of therapy. 
Bruce Logue, M.D. 
Frank Tutmji, 64.0. 
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